Gossamer Bio’s (GOSS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Gossamer Bio (NASDAQ:GOSS) in a research note published on Monday morning, Benzinga reports. They currently have a $10.00 target price on the stock.

A number of other equities analysts also recently issued reports on GOSS. The Goldman Sachs Group dropped their price target on Gossamer Bio from $9.00 to $8.00 and set a buy rating on the stock in a research note on Wednesday, March 6th. Wedbush began coverage on shares of Gossamer Bio in a research note on Friday, April 5th. They issued an outperform rating and a $4.00 price objective for the company. Finally, Piper Sandler restated an overweight rating and set a $15.00 price target on shares of Gossamer Bio in a report on Wednesday, March 27th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average price target of $7.65.

Gossamer Bio Trading Up 3.3 %

GOSS opened at $0.76 on Monday. The company has a debt-to-equity ratio of 3.14, a current ratio of 5.94 and a quick ratio of 5.94. Gossamer Bio has a one year low of $0.45 and a one year high of $1.88. The firm has a market capitalization of $170.89 million, a price-to-earnings ratio of -0.54 and a beta of 1.84. The business has a 50 day simple moving average of $1.08 and a two-hundred day simple moving average of $0.93.

Gossamer Bio (NASDAQ:GOSS) last released its earnings results on Tuesday, March 5th. The company reported ($0.21) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.21). Analysts predict that Gossamer Bio will post -0.75 EPS for the current year.

Insider Activity

In other news, CEO Faheem Hasnain sold 23,172 shares of the firm’s stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $1.16, for a total value of $26,879.52. Following the transaction, the chief executive officer now owns 120,293 shares in the company, valued at $139,539.88. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold 33,620 shares of company stock worth $39,682 over the last three months. 5.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Gossamer Bio

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Sivia Capital Partners LLC purchased a new stake in shares of Gossamer Bio in the 1st quarter valued at approximately $29,000. SG Americas Securities LLC purchased a new stake in Gossamer Bio in the first quarter valued at approximately $34,000. Financial Advocates Investment Management acquired a new position in Gossamer Bio during the third quarter worth $61,000. Bank of New York Mellon Corp lifted its stake in Gossamer Bio by 178.0% during the third quarter. Bank of New York Mellon Corp now owns 91,246 shares of the company’s stock worth $76,000 after purchasing an additional 58,428 shares in the last quarter. Finally, Citigroup Inc. boosted its position in shares of Gossamer Bio by 9,916.9% during the third quarter. Citigroup Inc. now owns 196,732 shares of the company’s stock worth $164,000 after buying an additional 194,768 shares during the period. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.